CA2284996A1 - 4,4-disubstituees-3,4-dihydro-2(1h)-quinazolinones utilisees comme inhibiteurs de la transcriptase inverse du vih - Google Patents
4,4-disubstituees-3,4-dihydro-2(1h)-quinazolinones utilisees comme inhibiteurs de la transcriptase inverse du vih Download PDFInfo
- Publication number
- CA2284996A1 CA2284996A1 CA002284996A CA2284996A CA2284996A1 CA 2284996 A1 CA2284996 A1 CA 2284996A1 CA 002284996 A CA002284996 A CA 002284996A CA 2284996 A CA2284996 A CA 2284996A CA 2284996 A1 CA2284996 A1 CA 2284996A1
- Authority
- CA
- Canada
- Prior art keywords
- ch2ch2
- pyridyl
- dihydro
- trifluoromethyl
- quinazolinone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La présente invention concerne 4,4-disubstituées-3,4-dihydro-2(1H)-quinazolinones de la formule (I) ou leurs formes stéréoisomères, leurs mélanges stéréoisomères ou encore leurs formes de sels pharmaceutiquement acceptables, ces composés étant utilisés comme inhibiteurs de la transcriptase inverse du VIH. L'invention concerne également des compositions et des kits de diagnostic comprenant ces composés, ainsi que leurs procédés d'utilisation dans le traitement des infections virales. Ces composés peuvent être également utilisés comme solutions étalons ou réactifs pour le dosage.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83854097A | 1997-04-09 | 1997-04-09 | |
US08/838540 | 1997-04-09 | ||
US7132298P | 1998-01-14 | 1998-01-14 | |
US60/071322 | 1998-01-14 | ||
PCT/US1998/006733 WO1998045276A2 (fr) | 1997-04-09 | 1998-04-07 | 4,4-disubstituees-3,4-dihydro-2(1h)-quinazolinones utilisees comme inhibiteurs de la transcriptase inverse du vih |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2284996A1 true CA2284996A1 (fr) | 1998-10-15 |
Family
ID=26752095
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002284996A Abandoned CA2284996A1 (fr) | 1997-04-09 | 1998-04-07 | 4,4-disubstituees-3,4-dihydro-2(1h)-quinazolinones utilisees comme inhibiteurs de la transcriptase inverse du vih |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP0973753A2 (fr) |
JP (1) | JP2002504095A (fr) |
KR (1) | KR20010006146A (fr) |
CN (1) | CN1252063A (fr) |
AR (1) | AR012340A1 (fr) |
AU (1) | AU734928B2 (fr) |
BR (1) | BR9808513A (fr) |
CA (1) | CA2284996A1 (fr) |
EA (1) | EA001991B1 (fr) |
EE (1) | EE9900452A (fr) |
HR (1) | HRP980143A2 (fr) |
HU (1) | HUP0001446A3 (fr) |
IL (1) | IL132188A0 (fr) |
NO (1) | NO314936B1 (fr) |
NZ (1) | NZ500592A (fr) |
PL (1) | PL336305A1 (fr) |
SK (1) | SK137899A3 (fr) |
TW (1) | TW587078B (fr) |
WO (1) | WO1998045276A2 (fr) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999050253A1 (fr) * | 1998-03-27 | 1999-10-07 | Du Pont Pharmaceuticals Company | 3,4-dihydro-2(1h)-quinazolinthiones substitues en 4,4, leur preparation et leur utilisation en tant qu'inhibiteurs de la transcriptase inverse du vih |
AU6508899A (en) | 1998-10-13 | 2000-05-01 | Du Pont Pharmaceuticals Company | Selective eradication of virally-infected cells by combined use of a cytotoxic agent and an antiviral agent |
US6225317B1 (en) * | 1998-11-19 | 2001-05-01 | Dupont Pharmaceuticals Company | Crystalline (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-3,4-dihydro-2(1H)-quinazolinone |
HRP990359A2 (en) * | 1998-11-19 | 2000-08-31 | Du Pont Pharm Co | A process for the preparation of quinazolinones |
US6175009B1 (en) | 1999-11-18 | 2001-01-16 | Dupont Pharmaceuticals Company | Process for the preparation of quinazolinones |
ATE305787T1 (de) | 1999-11-23 | 2005-10-15 | Smithkline Beecham Corp | 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren |
US6759410B1 (en) | 1999-11-23 | 2004-07-06 | Smithline Beecham Corporation | 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors |
US6555686B2 (en) | 2000-03-23 | 2003-04-29 | Bristol-Myers Squibb Pharma | Asymmetric synthesis of quinazolin-2-ones useful as HIV reverse transcriptase inhibitors |
AU2001249161A1 (en) * | 2000-03-23 | 2001-10-03 | Bristol-Myers Squibb Pharma Company | Asymmetric synthesis of quinazolin-2-ones useful as hiv reverse transcriptase inhibitors |
US6596729B2 (en) * | 2000-07-20 | 2003-07-22 | Bristol-Myers Squibb Company | Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors |
ZA200300255B (en) | 2000-07-20 | 2004-09-28 | Bristol Myers Squibb Pharma Co | Tricyclic 2-pyridone compounds useful as HIV reverse transcriptase inhibitors. |
US8641644B2 (en) | 2000-11-21 | 2014-02-04 | Sanofi-Aventis Deutschland Gmbh | Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means |
US9795747B2 (en) | 2010-06-02 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Methods and apparatus for lancet actuation |
US7025774B2 (en) | 2001-06-12 | 2006-04-11 | Pelikan Technologies, Inc. | Tissue penetration device |
US9226699B2 (en) | 2002-04-19 | 2016-01-05 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling module with a continuous compression tissue interface surface |
US9427532B2 (en) | 2001-06-12 | 2016-08-30 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US9248267B2 (en) | 2002-04-19 | 2016-02-02 | Sanofi-Aventis Deustchland Gmbh | Tissue penetration device |
US8784335B2 (en) | 2002-04-19 | 2014-07-22 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling device with a capacitive sensor |
US9314194B2 (en) | 2002-04-19 | 2016-04-19 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US8702624B2 (en) | 2006-09-29 | 2014-04-22 | Sanofi-Aventis Deutschland Gmbh | Analyte measurement device with a single shot actuator |
US7226461B2 (en) | 2002-04-19 | 2007-06-05 | Pelikan Technologies, Inc. | Method and apparatus for a multi-use body fluid sampling device with sterility barrier release |
US7547287B2 (en) | 2002-04-19 | 2009-06-16 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US9795334B2 (en) | 2002-04-19 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US8579831B2 (en) | 2002-04-19 | 2013-11-12 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
AU2003295940A1 (en) * | 2002-12-16 | 2004-07-29 | Boehringer Ingelheim Pharmaceuticals, Inc. | Treatment of hiv infection through combined administration of tipranavir and capravirine |
US8574895B2 (en) | 2002-12-30 | 2013-11-05 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus using optical techniques to measure analyte levels |
WO2006001797A1 (fr) | 2004-06-14 | 2006-01-05 | Pelikan Technologies, Inc. | Element penetrant peu douloureux |
US8282576B2 (en) | 2003-09-29 | 2012-10-09 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for an improved sample capture device |
EP1680014A4 (fr) | 2003-10-14 | 2009-01-21 | Pelikan Technologies Inc | Procede et appareil fournissant une interface-utilisateur variable |
WO2005065414A2 (fr) | 2003-12-31 | 2005-07-21 | Pelikan Technologies, Inc. | Procede et appareil permettant d'ameliorer le flux fluidique et le prelevement d'echantillons |
WO2006011062A2 (fr) | 2004-05-20 | 2006-02-02 | Albatros Technologies Gmbh & Co. Kg | Hydrogel imprimable pour biocapteurs |
EP1765194A4 (fr) | 2004-06-03 | 2010-09-29 | Pelikan Technologies Inc | Procede et appareil pour la fabrication d'un dispositif d'echantillonnage de liquides |
US9775553B2 (en) | 2004-06-03 | 2017-10-03 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for a fluid sampling device |
WO2009126900A1 (fr) | 2008-04-11 | 2009-10-15 | Pelikan Technologies, Inc. | Procédé et appareil pour dispositif de détection d’analyte |
US9375169B2 (en) | 2009-01-30 | 2016-06-28 | Sanofi-Aventis Deutschland Gmbh | Cam drive for managing disposable penetrating member actions with a single motor and motor and control system |
US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
US8965476B2 (en) | 2010-04-16 | 2015-02-24 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
CN102060786A (zh) * | 2011-01-20 | 2011-05-18 | 天津大学 | 4-(取代-1,3-二炔基)-4-(三氟甲基)-3,4-二氢取代喹唑啉-2-酮类化合物及其制备方法和应用 |
EP3173096A1 (fr) * | 2011-04-06 | 2017-05-31 | Biovaxim Limited | Compositions pharmaceutiques pour prévenir et/ou traiter une maladie vih chez l'homme |
US9365576B2 (en) | 2012-05-24 | 2016-06-14 | Novartis Ag | Pyrrolopyrrolidinone compounds |
US9556180B2 (en) | 2013-01-22 | 2017-01-31 | Novartis Ag | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction |
WO2014115077A1 (fr) | 2013-01-22 | 2014-07-31 | Novartis Ag | Composés de purinone substitués |
MX2015016344A (es) | 2013-05-27 | 2016-03-01 | Novartis Ag | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. |
PL3004112T3 (pl) | 2013-05-28 | 2018-02-28 | Novartis Ag | Pochodne pirazolo-pirolidyn-4-onu oraz ich zastosowanie w leczeniu choroby |
MX2015016421A (es) | 2013-05-28 | 2016-03-03 | Novartis Ag | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades. |
EP3071571A1 (fr) | 2013-11-21 | 2016-09-28 | Novartis AG | Dérivés de pyrrolopyrrolone et leur utilisation en tant qu'inhibiteurs de protéines bet |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL102764A0 (en) * | 1991-08-16 | 1993-01-31 | Merck & Co Inc | Quinazoline derivatives,and pharmaceutical compositions containing them |
AU2436792A (en) * | 1991-08-16 | 1993-03-16 | Merck & Co., Inc. | Quinazoline derivatives as inhibitors of hiv reverse transcriptase |
WO1993022292A1 (fr) * | 1992-05-07 | 1993-11-11 | Merck & Co., Inc. | Nouvelles quinazolines inhibant la transcriptase inverse du vih |
US5665720A (en) * | 1992-08-07 | 1997-09-09 | Merck & Co., Inc. | Benzoxazinones as inhibitors of HIV reverse transcriptase |
DE4320347A1 (de) * | 1993-06-19 | 1994-12-22 | Boehringer Mannheim Gmbh | Quinazolin-Derivate und diese enthaltende Arzneimittel |
GB2281297A (en) * | 1993-08-27 | 1995-03-01 | Merck & Co Inc | Quinazoline compounds |
AU1046895A (en) * | 1993-11-05 | 1995-05-23 | Merck & Co., Inc. | New quinazolines as inhibitors of hiv reverse transcriptase |
US5434152A (en) * | 1993-11-08 | 1995-07-18 | Merck & Co., Inc. | Asymmetric synthesis of (S)-(-)-6-chloro-4- cyclopropyl-3,4-dihydro-4-[(2-pyridyl)ethynyl]-2(1H)-quinazolinone |
-
1998
- 1998-03-19 HR HR60/071,322A patent/HRP980143A2/hr not_active Application Discontinuation
- 1998-04-06 AR ARP980101558A patent/AR012340A1/es not_active Application Discontinuation
- 1998-04-07 NZ NZ500592A patent/NZ500592A/en unknown
- 1998-04-07 PL PL98336305A patent/PL336305A1/xx unknown
- 1998-04-07 EE EEP199900452A patent/EE9900452A/xx unknown
- 1998-04-07 AU AU67960/98A patent/AU734928B2/en not_active Ceased
- 1998-04-07 JP JP54297198A patent/JP2002504095A/ja active Pending
- 1998-04-07 EP EP98913401A patent/EP0973753A2/fr not_active Withdrawn
- 1998-04-07 IL IL13218898A patent/IL132188A0/xx unknown
- 1998-04-07 BR BR9808513-1A patent/BR9808513A/pt not_active IP Right Cessation
- 1998-04-07 CA CA002284996A patent/CA2284996A1/fr not_active Abandoned
- 1998-04-07 WO PCT/US1998/006733 patent/WO1998045276A2/fr not_active Application Discontinuation
- 1998-04-07 SK SK1378-99A patent/SK137899A3/sk unknown
- 1998-04-07 HU HU0001446A patent/HUP0001446A3/hu unknown
- 1998-04-07 KR KR1019997009225A patent/KR20010006146A/ko not_active Application Discontinuation
- 1998-04-07 EA EA199900907A patent/EA001991B1/ru not_active IP Right Cessation
- 1998-04-07 CN CN98803974A patent/CN1252063A/zh active Pending
- 1998-04-15 TW TW087105365A patent/TW587078B/zh active
-
1999
- 1999-10-08 NO NO19994904A patent/NO314936B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
BR9808513A (pt) | 2000-05-23 |
NZ500592A (en) | 2001-09-28 |
NO314936B1 (no) | 2003-06-16 |
WO1998045276A3 (fr) | 1999-01-14 |
AU6796098A (en) | 1998-10-30 |
EP0973753A2 (fr) | 2000-01-26 |
EA199900907A1 (ru) | 2000-04-24 |
IL132188A0 (en) | 2001-03-19 |
NO994904L (no) | 1999-12-01 |
TW587078B (en) | 2004-05-11 |
EA001991B1 (ru) | 2001-10-22 |
AR012340A1 (es) | 2000-10-18 |
SK137899A3 (en) | 2000-05-16 |
KR20010006146A (ko) | 2001-01-26 |
HRP980143A2 (en) | 1999-02-28 |
HUP0001446A2 (hu) | 2001-05-28 |
AU734928B2 (en) | 2001-06-28 |
CN1252063A (zh) | 2000-05-03 |
JP2002504095A (ja) | 2002-02-05 |
EE9900452A (et) | 2000-04-17 |
PL336305A1 (en) | 2000-06-19 |
HUP0001446A3 (en) | 2001-11-28 |
NO994904D0 (no) | 1999-10-08 |
WO1998045276A2 (fr) | 1998-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU734928B2 (en) | 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones useful as HIV reverse transcriptase inhibitors | |
US6124302A (en) | 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones useful as HIV reverse transcriptase inhibitors | |
WO2003062238A1 (fr) | Composes 2-pyrimidones tricycliques utilises en tant qu'inhibiteurs de la transcriptase inverse du vih | |
EP1379248A1 (fr) | Composes tricycliques utiles en tant qu'inhibiteurs de transcriptase inverse vih | |
US6127375A (en) | 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinthiones useful as HIV reverse transcriptase inhibitors | |
US6204262B1 (en) | 1,3-Benzodiazepin-2-ones and 1,3-Benzoxazepin-2-ones useful as HIV reverse transcriptase inhibitors | |
US6489320B1 (en) | 5, 5-disubstituted-1, 5-dihydro-4, 1-benzoxazepin-2 (3H)-ones useful as HIV reverse transcriptase inhibitors | |
US6090821A (en) | Substituted quinolin-2 (1H)-ones useful as HIV reverse transcriptase inhibitors | |
US6946469B2 (en) | Cyanamide, alkoxyamino, and urea derivatives of 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones as HIV reverse transcriptase inhibitors | |
US20040063734A1 (en) | 4,4-Disubstituted-3,4-dihydro-2 (1H)-quinazoliniones useful as HIV reverse transcriptase inhibitors | |
US6462037B1 (en) | 1,4-benzodiazepin-2-ones useful as HIV reverse transcriptase inhibitors | |
US6265406B1 (en) | Substituted quinolin-2 (1H) -ones useful as HIV reverse transcriptase inhibitors | |
US7015214B2 (en) | Cyanamide, alkoxyamino, and urea derivatives of 1,3-benzodiazepine as HIV reverse transcriptase inhibitors | |
AU7371301A (en) | 4,4-disubstituted-3,4-dihydro-2-)1H)- quinazolinones useful as HIV reverse transcriptase inhibitors | |
CZ352499A3 (cs) | 4,4-Disubstituované-3,4-dihydro-2 (1H)- chinazolinony vhodné jako inhibitory HIV reverzní transkriptázy | |
MXPA99008909A (en) | 4,4-disubstituted-3,4-dihydro-2(1h)-quinazolinones useful as hiv reverse transcriptase inhibitors | |
AU2002254652A1 (en) | Tricyclic compounds useful as HIV reverse transcriptase inhibitors | |
AU2003203047A1 (en) | Tricyclic 2-pyrimidone compounds useful as HIV reverse transcriptase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |